Dermata Therapeutics (NASDAQ:DRMA) Shares Up 3%

Dermata Therapeutics, Inc. (NASDAQ:DRMAGet Free Report)’s stock price shot up 3% during trading on Friday . The stock traded as high as $0.44 and last traded at $0.43. 70,097 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 1,072,440 shares. The stock had previously closed at $0.42.

Dermata Therapeutics Price Performance

The company’s fifty day simple moving average is $0.48 and its 200 day simple moving average is $0.72.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DRMA. Citadel Advisors LLC purchased a new stake in shares of Dermata Therapeutics during the 2nd quarter valued at $29,000. Renaissance Technologies LLC purchased a new position in Dermata Therapeutics in the 1st quarter worth $34,000. Raymond James Financial Services Advisors Inc. purchased a new position in Dermata Therapeutics in the 4th quarter worth $58,000. Acadian Asset Management LLC raised its position in Dermata Therapeutics by 34.2% in the 3rd quarter. Acadian Asset Management LLC now owns 75,538 shares of the company’s stock worth $79,000 after purchasing an additional 19,253 shares during the period. Finally, Armistice Capital LLC bought a new stake in Dermata Therapeutics in the 4th quarter worth $133,000. 17.78% of the stock is owned by institutional investors.

Dermata Therapeutics Company Profile

(Get Free Report)

Dermata Therapeutics, Inc, a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.

Read More

Receive News & Ratings for Dermata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.